Doxycycline — Doxycycline 100mg, 60 Capsules

Doxycycline — 60 Capsules (1 Bottle)

This product listing features a complete bottle containing 60 capsules of Doxycycline. This standardized volume is optimized to provide a highly precise and consistent supply for continuous evaluation, multi-cycle research, and therapeutic modeling within advanced oncology, cellular longevity, and metabolic frameworks.

General Pharmaceutical & Chemical Information

• Active Ingredient: Doxycycline hyclate
• Dosage: 100 mg of Doxycycline per capsule
• Purity: 99%+ Purity (Lab Tested, Pharmaceutical Grade)
• Other Components: Gelatin (capsule), lactose monohydrate, calcium stearate
• Package Size: 1 Bottle (60 capsules)
• CAS Number: 24390-14-5 (Doxycycline hyclate)
• Molecular Formula: C22H24N2O8⋅HCl⋅0.5H2O⋅0.5C2H6O
• Form: Small-molecule compound enclosed in capsules
• Application: For Research Applications Only.

Primary Therapeutic Focus: Oncology Prevention & Management (Off-Label Context)

While traditionally classified as a tetracycline antibiotic, Doxycycline has emerged in advanced translational oncology as a potent, multi-targeted metabolic agent. Sub-antimicrobial dosing (low-dose protocols) is actively researched to exploit specific cellular vulnerabilities unique to malignant cell progression.

• Targeting Cancer Stem Cells (CSCs): Cancer stem cells are highly resilient subpopulations driving chemotherapy resistance, recurrence, and metastatic spread. Doxycycline selectively targets CSCs by inhibiting mitochondrial biogenesis. Because mitochondria in cancer stem cells share evolutionary origins with bacteria, low-dose Doxycycline restricts their protein translation, effectively neutralizing their self-renewal capacity.
• Suppression of Matrix Metalloproteinases (MMPs): Doxycycline is a potent inhibitor of matrix metalloproteinases (specifically MMP-2 and MMP-9). In an oncology framework, suppressing MMP activity stops the degradation of the extracellular matrix, directly hindering tumor cell invasion, migration, and angiogenesis (the formation of new blood vessels feeding the tumor).
• Disruption of Tumor Microenvironment & Cross-talk: By suppressing critical signaling pathways, it interferes with the metabolic symbiosis between stromal cells and malignant cells, limiting the energy supply required for aggressive tumor growth.

Anti-Aging & Longevity Properties (Geroprotection)

Beyond its primary oncological research applications, low-dose Doxycycline acts as a systemic metabolic and inflammatory modulator to slow the processes of biological aging.

• Anti-Inflammatory Action & Inflammaging Control: At sub-antibacterial doses, it downregulates critical pro-inflammatory cytokines (such as TNF-α and IL-6) and inhibits NF-κB signaling. This helps mitigate inflammaging—the systemic, low-grade chronic inflammation that damages tissues over time.
• Cellular Stress Modulation: Preclinical data suggests it can lower oxidative stress parameters and improve mitochondrial structural resilience under metabolic strain.
• Neuroprotective Potential: Experimental models indicate a clear reduction in neuroinflammation and a structural limitation of toxic protein aggregation, which are foundational mechanisms studied in Alzheimer’s and Parkinson’s disease research.

Strict Regulatory Disclaimer: This product is intended solely for laboratory research, in vitro evaluation, and analytical purposes. We do not provide medical advice, recommend specific protocols, or guarantee any therapeutic results. Nothing stated herein should be construed as a medical recommendation or a guarantee of efficacy in treating, curing, or preventing any disease, including cancer. Any practical application of this compound must be strictly validated by independent research and overseen by a qualified professional.